CLS-AX

DRUG3 trials

Sponsors

Clearside Biomedical, Inc.

Conditions

Neovascular Age-related Macular Degeneration

Phase 1

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

CompletedNCT04626128

Clearside Biomedical, Inc.Neovascular Age-related Macular Degeneration

Start: 2020-12-15End: 2022-10-13Updated: 2023-09-18

Phase 2

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

CompletedNCT05891548

Clearside Biomedical, Inc.Neovascular Age-related Macular Degeneration

Start: 2023-05-31End: 2024-08-20Updated: 2025-07-25

Unknown Phase

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

CompletedNCT05131646

Clearside Biomedical, Inc.Neovascular Age-related Macular Degeneration

Start: 2021-10-08End: 2023-01-05Updated: 2024-03-04